5626-85-7

Upstream product

• 420-04-2 CYANAMID 
• 6101-31-1 sulfanilamide hydrochloride 
• 63-74-1 sulfanilamide 
• 4023-02-3 1H-pyrazole-1-carboximidamide hydrochloride 
• 15150-25-1 N-cyanobenzamide 

Downstream Products

• 1421693-64-2 C₁₇H₁₈N₆O₂S₂ 
• 1421693-63-1 C₁₄H₁₄N₆O₂S₂ 
• 1421693-66-4 C₁₅H₁₃F₃N₆O₂S₂ 
• 1415509-36-2 C₂₃H₁₉N₇O₂S 
• 1415509-34-0 C₂₀H₂₀N₆O₂S 
• 1415509-27-1 C₁₉H₁₈N₆O₂S 
• 1415509-25-9 C₁₈H₁₆N₆O₂S 
• 1402451-92-6 C₁₉H₂₀N₆O₃S 
• 1402452-04-3 C₁₅H₁₂ClN₅O₂S 
• 1239409-73-4 C₁₉H₁₈N₄O₃S 
• 1239410-85-5 C₁₄H₁₂N₄O₂S₂ 
• 1239410-58-2 C₁₈H₁₇N₅O₂S 
• 1348399-58-5 4-[4-(4-Nitro-phenyl)-pyrimidin-2-ylamino]-benzenesulfonamide 

Relevant academic research and scientific papers

Identification of pyrimidine derivatives as hSMG-1 inhibitors

hSMG-1 kinase plays a dual role in a highly conserved RNA surveillance pathway termed nonsense-mediated RNA decay (NMD) and in cellular genotoxic stress response. Since deregulation of cellular responses to stress contributes to tumor growth and resistance to chemotherapy, hSMG-1 is a potential target for cancer treatment. From our screening efforts, we have identified pyrimidine derivatives as hSMG-1 kinase inhibitors. We report structure-based optimization of this pan-kinase scaffold to improve its biochemical profile and overall kinome selectivity, including mTOR and CDK, to generate the first reported selective hSMG-1 tool compound.

PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM

The present invention relates to pyrimidine sulfonamide analogs, methods of making pyrimidine sulfonamide analogs, compositions comprising a pyrimidine sulfonamide analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a pyrimidine sulfonamide analog.

Anilino-pyrimidine analogs

The present invention relates to compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are defined herein.

IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES

A compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl; Ris as defined within; m is 0-5; wherein the values of Rmay be the same or different; Ris as defined within; n is 0 to 2, wherein the values of Rmay be the same or different; Ring B is phenyl or phenyl fused to a C5-7cycloalkyl ring; Ris as defined within; p is 0-4; wherein the values of Rmay be the same or different; Ris as defined within; q is 0-2; wherein the values of Rmay be the same or different; and wherein p+q=5; or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

The present invention provides compounds of formula I: wherein G is a small group selected from hydrogen or C1-3 alkyl, Q is pyridine or pyrimidine, and R1-R3 are as defined in the specification. These compounds are select